Company Profile

Tricida, Inc. is a pharmaceutical company. The Company is focused on its investigational drug candidate, veverimer (TRC101). TRC101 is a non-absorbed, orally administered polymer designed to treat metabolic acidosis and slow CKD progression by binding and removing acid from the gastrointestinal (GI) tract. Its veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. Veverimer is a single, high molecular weight, crosslinked polyamine molecule. The size of veverimer prevents systemic absorption from the GI tract. The high degree of cross-linking within veverimer limits swelling and the overall volume in the GI tract, with the goal of facilitating GI tolerability. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD.

Employees

Sector

Biotechnology & Medical Research

More about the company

12/06/23	Tricida, Inc. Went Out of Business	CI
01/06/23	First Motion for Exclusivity Period Extension Approved For Tricida, Inc.	CI
23/05/23	Fifth Amended Liquidation Plan Approved for Tricida, Inc.	CI
22/05/23	Fifth Amended Liquidation Plan Filed by Tricida, Inc.	CI
12/05/23	Fourth Amended Liquidation Plan Filed by Tricida, Inc.	CI
08/05/23	First Motion for Exclusivity Period Extension Filed by Tricida, Inc.	CI
27/03/23	Fourth Amended Disclosure Statement Approved for Tricida, Inc.	CI
24/03/23	Fourth Amended Disclosure Statement Filed by Tricida, Inc.	CI
21/03/23	Third Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	CI
26/02/23	Second Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	CI
24/02/23	First Amended Liquidation Plan and Disclosure Statement Filed by Tricida, Inc.	CI
22/02/23	Motion for Asset Sale Approved for Tricida, Inc.	CI
22/02/23	Motion for Asset Sale Approved for Tricida, Inc.	CI

25/10/22	Needham Downgrades Tricida to Hold From Buy	MT
25/10/22	JPMorgan Downgrades Tricida to Underweight From Neutral	MT
24/10/22	Cowen Downgrades Tricida to Market Perform From Outperform, Removes $20 Price Target	MT
24/05/22	Goldman Sachs Adjusts Price Target for Tricida to $16 From $22, Keeps Buy Rating	MT
11/05/22	Goldman Sachs Adjusts Tricida Price Target to $22 From $25, Maintains Buy Rating	MT

16/03/23	Tricida : Acquisition/Asset Disposal - Form 8-K	PU
25/02/23	TRICIDA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
24/02/23	TRICIDA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
18/02/23	TRICIDA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
28/01/23	TRICIDA, INC. : Financial Statements and Exhibits (form 8-K)	AQ

Director	Title	Age	Since
Robert Alpern BRD	Director/Board Member	75	01/10/2013
Thomas FitzGerald BRD	Director/Board Member	-	09/01/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/11/22	Robert Alpern	Sell	Director	131,879	0.2369%
22/11/22	OrbiMed Advisors Private Equity	Sell	Company	10,280,947	18.4680%
22/11/22	OrbiMed Advisors Private Equity	Sell	Company	10,280,947	18.4680%

Tricida, Inc. Stock

Stocks

TCDA

US89610F1012

Biotechnology & Medical Research

Latest news: Tricida, Inc.

Analysts' recommendations: Tricida, Inc.

Press Releases: Tricida, Inc.

Quotes and Performance

Managers and Directors: Tricida, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRICIDA, INC.	-99.90%	-99.92%	-	-	580
WUXI APPTEC CO., LTD.	+0.34%	+1.12%	+34.75%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.68%	+12.25%	+82.98%	55.53B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+103.69%	53.03B
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+52.86%	45.99B
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+117.99%	42.45B
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+922.41%	40.45B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+88.74%	34.47B
CELLTRION, INC.	-0.26%	-2.57%	+12.55%	+45.18%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	+0.49%	-1.14%	+23.78%	-10.34%	24.23B
Average	-9.98%	+4.29%	+52.51%	+162.73%	43.62B
Weighted average by Cap.	+0.12%	+3.59%	+49.33%	+160.59%